Skip to content

Active Surveillance and Surgery Outcomes in Low Risk Papillary Thyroid Cancer

Papillary Thyroid Carcinoma | Papillary Thyroid Cancer | Papillary Microcarcinoma of the Thyroid

This is a prospective, observational, multi-center study examining the long-term outcomes of patients with small, low risk papillary thyroid cancer who offered the choice of active surveillance (close follow-up to monitor for potential disease progression) or immediate surgery.

null

Participation Requirements

  • Sex:

    ALL
  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

* Patients 18 years of age or older.
* Newly diagnosed previously surgically untreated papillary thyroid cancer (PTC) or suspicious for PTC on fine needle aspiration biopsy of the thyroid. PTC must be \< 2 cm in maximal diameter on thyroid ultrasound.
* The absence of metastatic cervical lymphadenopathy or gross extrathyroidal extension of PTC, as confirmed on neck ultrasound imaging.
* The absence of other current absolute indication for thyroid or parathyroid surgery (e.g. severe hyperthyroidism that cannot be controlled medically, large goitre with severe compressive symptoms, or primary hyperthyroidism meeting surgical criteria).

Exclusion Criteria:

* Metastatic thyroid cancer (lymph nodes or distant).
* History of prior thyroid surgery for any indication.
* The primary PTC being on the trachea or immediately adjacent to the recurrent laryngeal nerve, and with progression would be deemed to be at high risk of growth into these critical structures.
* Clinical signs, imaging, or laryngoscopy findings suggestive of locally advanced thyroid cancer (i.e. vocal cord paralysis due to the thyroid cancer or any clinical or radiographic signs of extrathyroidal invasion into adjacent structures such as the strap muscles of the neck, trachea or esophagus).
* Known/suspected poorly differentiated or non-papillary thyroid cancer.
* Medically unfit for surgery due to severe co-morbidity. Severe comorbidity may include another active malignancy with limited life expectancy of \< 1 year).
* Pregnancy at the time of study enrollment.
* Unable/unwilling to provide informed consent for the study or comply with study follow-up procedures due to current active physical limitations/medical co-morbidity, cognitive, or psychiatric impairment substance abuse, or other reasons.

Study Location

St. Joseph's Healthcare
St. Joseph's Healthcare
Hamilton, Ontario
Canada

Contact Study Team

Backup Contact

Han Zhang

Primary Contact

Han Zhang

[email protected]
905-522-1155
Backup Contact

Michael Au

[email protected]
905-522-1155
CHU de Québec - Université Laval
CHU de Québec - Université Laval
Québec, Quebec
Canada

Contact Study Team

Backup Contact

Maryse Brassard, MD

Primary Contact

Sarah Chouinard-Castonguay

[email protected]
418-654-2169
Backup Contact

Nathalie Audet, MD

Nova Scotia Health
Nova Scotia Health
Halifax, Nova Scotia
Canada

Contact Study Team

Backup Contact

Martin Corsten, MD

Primary Contact

Martin Corsten

(902) 473-4420
Division chirurgie ORL et cervico-faciale
Division chirurgie ORL et cervico-faciale
Montreal, Quebec
Canada

Contact Study Team

Primary Contact

Guillaume Cardin

[email protected]
514 890-8000
Backup Contact

Eric Bissada

Backup Contact

Hortensia Mircescu

University of Calgary, Cumming School of Medicine
University of Calgary, Cumming School of Medicine
Calgary, Alberta
Canada

Contact Study Team

Backup Contact

Shamir Chandarana

Backup Contact

Sana Ghaznavi

Primary Contact

Debbie Lamb

[email protected]
403-955-8689
Lawson Health Research Institute
Lawson Health Research Institute
London, Ontario
Canada

Contact Study Team

Primary Contact

Halema Khan

[email protected]
(519) 685-8500
Backup Contact

Deric Morrison, MD

Backup Contact

Adrian Mendez, MD, PhD

[email protected]
(519) 685-8058
Backup Contact

Adrian Mendez, MD, PhD

University of British Columbia
University of British Columbia
Vancouver, British Columbia
Canada

Contact Study Team

Primary Contact

Elnaz Roohi

[email protected]
604 537 3075
Backup Contact

Eitan Prisman

University Health Network
University Health Network
Toronto, Ontario
Canada

Contact Study Team

Primary Contact

Anna Sawka, MD, PhD

[email protected]
(416) 340-4800
Backup Contact

Anna M Sawka, MD, PhD

Backup Contact

Anna M Sawka, MD, PhD

[email protected]
(416) 340-3678
Backup Contact

David P Goldstein, MD, MSc

Study Sponsored By
University Health Network, Toronto
Participants Required
More Information
Study ID: NCT04624477